Please login to order a test.
- Beta-Strep (Group B) Antigen
Aid in documentation of active beta streptococcal infection
Latex agglutination (LA)
Group B Streptococcus is currently one of the most significant human pathogens in the neonatal period. The most common mode of acquisition by the neonate is exposure to the maternal genital flora in utero through ruptured membranes or by contamination during passage through the birth canal. Rapid identification of group B Streptococcus carriers is important in management of premature rupture of the membranes because the effectiveness of intrapartum prophylactic ampicillin may be compromised by awaiting the results of conventional cultures. Infection is manifested in two major forms, early onset septicemic infection manifest in the first few days of life and late onset meningitis which occurs during the first few months of life.
Increased isolation of strains of group B Streptococcus resistant to erythromycin (9%) or intermediate susceptible clindamycin (9.5%) and cefoxitin (15.3%) have been reported. Nineteen percent exhibited a multiple antibiotic resistance pattern. Penicillinase production and resistance to ampicillin were not encountered in the particular series. Susceptibility testing may be useful in selecting alternate antibiotic regimens.
Serum, urine (random), or cerebrospinal fluid (CSF)
1 mL serum, 5 mL urine, or 0.5 mL CSF
Indicate source of specimen.
Submit only one specimen per test request form. State source.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|018804||Beta Strep (Group B) Antigen||20459-4||018804||Beta Strep (Group B) Antigen||20459-4|